These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21292779)

  • 1. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
    Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
    Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
    Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
    Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.
    Conforti FL; Spataro R; Sproviero W; Mazzei R; Cavalcanti F; Condino F; Simone IL; Logroscino G; Patitucci A; Magariello A; Muglia M; Rodolico C; Valentino P; Bono F; Colletti T; Monsurrò MR; Gambardella A; La Bella V
    Neurology; 2012 Dec; 79(24):2315-20. PubMed ID: 23197749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
    Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
    Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
    Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
    Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
    PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
    Figley MD; Thomas A; Gitler AD
    Neurobiol Aging; 2014 Apr; 35(4):936.e1-4. PubMed ID: 24269018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
    Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
    Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
    Bonini NM; Gitler AD
    J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
    Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
    Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
    van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
    Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis.
    Chen Y; Huang R; Yang Y; Chen K; Song W; Pan P; Li J; Shang HF
    Neurobiol Aging; 2011 Oct; 32(10):1925.e1-5. PubMed ID: 21741123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
    Elden AC; Kim HJ; Hart MP; Chen-Plotkin AS; Johnson BS; Fang X; Armakola M; Geser F; Greene R; Lu MM; Padmanabhan A; Clay-Falcone D; McCluskey L; Elman L; Juhr D; Gruber PJ; Rüb U; Auburger G; Trojanowski JQ; Lee VM; Van Deerlin VM; Bonini NM; Gitler AD
    Nature; 2010 Aug; 466(7310):1069-75. PubMed ID: 20740007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.
    Van Langenhove T; van der Zee J; Engelborghs S; Vandenberghe R; Santens P; Van den Broeck M; Mattheijssens M; Peeters K; Nuytten D; Cras P; De Deyn PP; De Jonghe P; Cruts M; Van Broeckhoven C
    Neurobiol Aging; 2012 May; 33(5):1004.e17-20. PubMed ID: 22035589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.
    Lattante S; Millecamps S; Stevanin G; Rivaud-Péchoux S; Moigneu C; Camuzat A; Da Barroca S; Mundwiller E; Couarch P; Salachas F; Hannequin D; Meininger V; Pasquier F; Seilhean D; Couratier P; Danel-Brunaud V; Bonnet AM; Tranchant C; LeGuern E; Brice A; Le Ber I; Kabashi E;
    Neurology; 2014 Sep; 83(11):990-5. PubMed ID: 25098532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis.
    Narain P; Gomes J; Bhatia R; Singh I; Vivekanandan P
    Neurobiol Aging; 2017 Aug; 56():211.e9-211.e14. PubMed ID: 28527524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Huntington's disease gene CAG repeat alleles in sporadic amyotrophic lateral sclerosis patients.
    Ramos EM; Keagle P; Gillis T; Lowe P; Mysore JS; Leclerc AL; Ratti A; Ticozzi N; Gellera C; Gusella JF; Silani V; Alonso I; Brown RH; MacDonald ME; Landers JE
    Amyotroph Lateral Scler; 2012 May; 13(3):265-9. PubMed ID: 22409360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis.
    Liu X; Lu M; Tang L; Zhang N; Chui D; Fan D
    Neurobiol Aging; 2013 Sep; 34(9):2236.e5-8. PubMed ID: 23635656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry.
    Borghero G; Pugliatti M; Marrosu F; Marrosu MG; Murru MR; Floris G; Cannas A; Parish LD; Cau TB; Loi D; Ticca A; Traccis S; Manera U; Canosa A; Moglia C; Calvo A; Barberis M; Brunetti M; Renton AE; Nalls MA; Traynor BJ; Restagno G; Chiò A;
    Neurobiol Aging; 2015 Oct; 36(10):2906.e1-5. PubMed ID: 26208502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.